Feb 27, 2018

A new phase I clinical trial to evaluate the safety and maximum tolerated dosage of a five-drug targeted combination therapy called ViPOR for patients with relapsed and treatment-resistant, or refractory, B-cell lymphomas is open at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Read more…

Feb 26, 2018

A newly funded study aims to explore the relationship between chronic inflammation, ancestry and tumor biology as a cause of prostate cancer progression in men of African descent who experience a disproportionately high prostate cancer mortality rate in the U.S. and globally. As a collaborative project between NCI and external researchers, Stefan Ambs, Ph.D., M.P.H, Senior Investigator in CCR’s Laboratory of Human Carcinogenesis, will lead the study with Michael Cook, Ph.D., of NCI’s Division of Cancer Epidemiology and Genetics and Clayton Yates, Ph.D., of Tuskegee University to help address health disparities for prostate cancer. The project is funded through a Prostate Cancer Research Program Impact Award from the Department of Defense. Read more...

Feb 23, 2018

The Federal Laboratory Consortium for Technology Transfer has recognized three CCR accomplishments with Excellence in Technology Transfer Awards. This award category honors employees of FLC member laboratories and non-laboratory staff who have accomplished outstanding work in the process of transferring federally developed technology. Read more…

Feb 22, 2018

Drs. Tracie Miller and Steve Lipshultz have spent their careers caring for pediatric patients and conducting research at well-known medical institutions across the country. In some ways, those years of providing patient care and conducting medical research prepared the couple for Tracie’s ovarian cancer diagnosis, and in other ways, it didn’t. Read more...

Feb 20, 2018

Adults diagnosed with thymic carcinoma who overexpress the protein mesothelin may be eligible to participate in a new clinical trial at the NIH Clinical Center. The study will look at the safety and effectiveness of an investigational drug, anetumab ravtansine, developed by Bayer HealthCare Pharmaceuticals. The drug works by binding to mesothelin, therefore overexpression of the protein could be useful for targeting cancer cells. Read more...

Feb 20, 2018

Adults diagnosed with thymic carcinoma who overexpress the protein mesothelin may be eligible to participate in a new clinical trial at the NIH Clinical Center. The study will look at the safety and effectiveness of an investigational drug, anetumab ravtansine, developed by Bayer HealthCare Pharmaceuticals. The drug works by binding to mesothelin, therefore overexpression of the protein could be useful for targeting cancer cells. Read more...

Feb 20, 2018

Michael Gottesman, M.D., Chief of the Laboratory of Cell Biology, has received the Dr. Nathan Davis Award for Outstanding Government Service from the American Medical Association (AMA) for his contributions to public health, medical science and the training of physician-scientists. As the AMA’s top government service award, the Dr. Nathan Davis Award recognizes elected and career officials in federal, state or municipal service whose outstanding contributions have promoted the art and science of medicine and the betterment of public health. Read more…

Feb 15, 2018

The National Foundation for Cancer Research (NFCR) will honor CCR’s Doug Lowy, M.D., Chief of the Laboratory of Cellular Oncology, and John Schiller, Ph.D., Deputy Chief of the Laboratory of Cellular Oncology, with the Szent-Györgyi Prize for Progress in Cancer Research during a ceremony on May 5 in Washington, D.C. The annual prize, named after NFCR’s co-founder, Albert Szent-Györgyi, M.D., Ph.D., honors scientists who have made an original discovery or breakthrough in scientific understanding that has had a lasting impact on the cancer field and saving people’s lives. In addition to the more than 150 papers co-authored by Drs. Lowy and Schiller, the duo’s research has led to great advances in understanding HPV infection and the development of three preventive HPV vaccines approved by the U.S. Food and Drug Administration. Read more…

Feb 14, 2018

Lucy was diagnosed with Hyper IgE syndrome or Job’s syndrome – a rare genetic illness that puts her at risk for developing serious lung and skin infections. Avery has a rare NFKB1 gene mutation that compromises her immune system. For both patients, clinical trials at the Center for Cancer Research provided life-saving bone marrow transplants to address infections caused by immune deficiencies. Lucy and Avery stay at The Children’s Inn when they come to NIH for treatment. Read Lucy’s story (page 3) and Avery’s story (page 5) in the Children’s Inn Annual Report…

Feb 13, 2018

The NCI Center for Cancer Research (CCR) and Division of Cancer Epidemiology and Genetics (DCEG), and the Frederick National Laboratory for Cancer Research (FNLCR) will hold their 14th Annual Retreat for all Staff Scientists and Staff Clinicians on April 6, 2018. This year's topic is "Cutting Edge in Cancer Research: Cancer Immunotherapy".  The registration deadline is February 23 and abstracts must be submitted by February 15.  Learn more...